Candel Therapeutics To Present Data From Its Phase 2 Clinical Trial Of CAN-2409 At ASCO
Portfolio Pulse from Benzinga Newsdesk
Candel Therapeutics is set to present data from its Phase 2 clinical trial of CAN-2409 at the American Society of Clinical Oncology (ASCO). The treatment has shown a favorable safety and tolerability profile in non-small cell lung cancer (NSCLC) as of the data cut-off date.
May 23, 2024 | 9:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Candel Therapeutics will present Phase 2 trial data for CAN-2409 at ASCO, showing favorable safety and tolerability in NSCLC. This could positively impact the stock price.
The presentation of positive Phase 2 trial data at a major oncology conference like ASCO is likely to generate investor interest and potentially drive up the stock price. The favorable safety and tolerability profile in NSCLC is a significant milestone for the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100